These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 14625471

  • 21. Fas and Fas ligand expression on human peripheral blood leukocytes.
    Mincheff M, Loukinov D, Zoubak S, Hammett M, Meryman H.
    Vox Sang; 1998; 74(2):113-21. PubMed ID: 9501411
    [Abstract] [Full Text] [Related]

  • 22. Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy.
    Sheppard R, Bedi M, Kubota T, Semigran MJ, Dec W, Holubkov R, Feldman AM, Rosenblum WD, McTiernan CF, McNamara DM, IMAC Investigators.
    J Am Coll Cardiol; 2005 Sep 20; 46(6):1036-42. PubMed ID: 16168288
    [Abstract] [Full Text] [Related]

  • 23. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
    Korkolopoulou P, Goudopoulou A, Voutsinas G, Thomas-Tsagli E, Kapralos P, Patsouris E, Saetta AA.
    Urology; 2004 Jun 20; 63(6):1198-204. PubMed ID: 15183989
    [Abstract] [Full Text] [Related]

  • 24. Apoptosis of peripheral blood mononuclear cells in Kawasaki disease.
    Kim HY, Lee HG, Kim DS.
    J Rheumatol; 2000 Mar 20; 27(3):801-6. PubMed ID: 10743828
    [Abstract] [Full Text] [Related]

  • 25. Apoptosis of bovine ovarian surface epithelial cells by Fas antigen/Fas ligand signaling.
    Margalit KA, Cowan RG, Harman RM, Quirk SM.
    Reproduction; 2005 Nov 20; 130(5):751-8. PubMed ID: 16264104
    [Abstract] [Full Text] [Related]

  • 26. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.
    Cerrato JA, Khan T, Koul D, Lang FF, Conrad CA, Yung WK, Liu TJ.
    Int J Oncol; 2004 Feb 20; 24(2):409-17. PubMed ID: 14719118
    [Abstract] [Full Text] [Related]

  • 27. ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in Taiwan cobra phospholipase A(2)-treated U937 cells.
    Liu WH, Cheng YC, Chang LS.
    J Cell Physiol; 2009 Jun 20; 219(3):642-51. PubMed ID: 19180563
    [Abstract] [Full Text] [Related]

  • 28. Mifepristone regulates expression of apoptosis related genes Fas and FasL in mouse endometrium.
    Gao F, Xu FH, Zhou XC, Han XB, Liu YX.
    Acta Pharmacol Sin; 2001 Jun 20; 22(6):524-9. PubMed ID: 11747759
    [Abstract] [Full Text] [Related]

  • 29. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.
    Arts HJ, de Jong S, Hollema H, Ten Hoor KA, de Vries EG, van der Zee AG.
    Int J Oncol; 2005 Feb 20; 26(2):379-84. PubMed ID: 15645122
    [Abstract] [Full Text] [Related]

  • 30. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
    Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J.
    J Am Coll Cardiol; 2005 Apr 05; 45(7):1018-24. PubMed ID: 15808757
    [Abstract] [Full Text] [Related]

  • 31. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
    Shimizu M, Kondo M, Ito Y, Kume H, Suzuki R, Yamaki K.
    Cancer Detect Prev; 2005 Apr 05; 29(2):175-80. PubMed ID: 15829378
    [Abstract] [Full Text] [Related]

  • 32. Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-kappaB-mediated expression in cultured human mesangial cells.
    Tsukinoki T, Sugiyama H, Sunami R, Kobayashi M, Onoda T, Maeshima Y, Yamasaki Y, Makino H.
    Clin Exp Nephrol; 2004 Sep 05; 8(3):196-205. PubMed ID: 15480896
    [Abstract] [Full Text] [Related]

  • 33. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
    Imai T, Adachi S, Nishijo K, Ohgushi M, Okada M, Yasumi T, Watanabe K, Nishikomori R, Nakayama T, Yonehara S, Toguchida J, Nakahata T.
    Oncogene; 2003 Dec 18; 22(58):9231-42. PubMed ID: 14647441
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Arachidonic acid induces Fas and FasL upregulation in human leukemia U937 cells via Ca2+/ROS-mediated suppression of ERK/c-Fos pathway and activation of p38 MAPK/ATF-2 pathway.
    Liu WH, Chang LS.
    Toxicol Lett; 2009 Dec 15; 191(2-3):140-8. PubMed ID: 19720122
    [Abstract] [Full Text] [Related]

  • 36. Analysis of the expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders.
    Chen S, Fazle Akbar SM, Zhen Z, Luo Y, Deng L, Huang H, Chen L, Li W.
    Cell Mol Immunol; 2004 Jun 15; 1(3):224-8. PubMed ID: 16219172
    [Abstract] [Full Text] [Related]

  • 37. Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity.
    Matter-Reissmann UB, Sonntag KC, Gilli UO, Leguern C, Schneider MK, Seebach JD.
    Xenotransplantation; 2004 Jan 15; 11(1):43-52. PubMed ID: 14962292
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
    Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R, Lunardi C.
    Int Immunol; 2009 Mar 15; 21(3):237-43. PubMed ID: 19181929
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.